Nabaxor (Rivaroxaban)

Rivaroxaban, the active ingredient in Nabaxor, is a direct factor Xa inhibitor presented as an oral tablet for oral use. It is indicated for stroke prevention in non‑valvular atrial fibrillation and for treatment and secondary prevention of deep vein thrombosis and pulmonary embolism.

GNH USA supplies Nabaxor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rivaroxaban acts on the coagulation cascade to reduce thrombus formation in several venous and arterial conditions. - Non‑valvular atrial fibrillation: prevents stroke and systemic embolism. - Deep vein thrombosis (DVT): treats acute clot formation. - Pulmonary embolism (PE): treats acute clot formation and reduces recurrence risk.

Rivaroxaban may cause bleeding‑related reactions and other adverse events.

Common Side Effects: - Bruising: mild to moderate skin discoloration at sites of minor trauma. - Nosebleeds: occasional epistaxis without severe sequelae. - Headache: transient mild to moderate intensity. - Gastrointestinal upset: nausea or diarrhea.

Serious or Rare Side Effects: - Intracranial hemorrhage: life‑threatening bleeding within the skull. - Spinal or epidural hematoma: bleeding that may cause spinal cord compression. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver injury: abnormal hepatic enzymes or hepatitis.

Before initiating rivaroxaban therapy, consider patient‑specific risk factors and monitor appropriately. - Renal impairment: assess kidney function and adjust therapy as directed. - Hepatic disease: use with caution in patients with active liver disease. - Concomitant antiplatelet agents: increased risk of bleeding, monitor closely. - Surgery or invasive procedures: discontinue according to clinical guidelines to reduce bleeding risk. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Rivaroxaban interacts with several drug classes that may alter its anticoagulant effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Other anticoagulants (e.g., warfarin, heparin): additive bleeding risk.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs, e.g., ibuprofen): increased gastrointestinal bleeding risk. - Selective serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine): potential for enhanced bleeding.